Larger helical populations in peptides derived from the dimerization helix of the capsid protein of HIV-1 results in peptide binding toward regions other than the "hotspot" interface

Biomacromolecules. 2011 Sep 12;12(9):3252-64. doi: 10.1021/bm2007168. Epub 2011 Jul 26.

Abstract

The C-terminal domain (CTD) of the capsid protein (CA) of HIV-1 participates both in the formation of CA hexamers and in the joining of hexamers through homodimerization to form the viral capsid. Intact CA and the CTD are able to homodimerize with similar affinity (~15 μM); CTD homodimerization involves mainly an α-helical region. We have designed peptides derived from that helix with predicted higher helical propensities than the wild-type sequence while keeping residues important for dimerization. These peptides showed a higher helicity than that of the wild-type peptide, although not as high as theoretically predicted, and proved to be able to self-associate with apparent affinities similar to that of the whole CTD. However, binding to CTD mainly occurs at the last helical region of the protein. Accordingly, most of those peptides are unable to inhibit CA polymerization in vitro. Therefore, there is a subtle tuning between monomer-monomer interactions important for CTD dimerization and the maximal helical content achieved by the wild-type sequence of the interface.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Sequence
  • Binding Sites
  • Capsid Proteins / chemistry*
  • Capsid Proteins / genetics
  • Capsid Proteins / metabolism
  • Circular Dichroism
  • Dimerization
  • HIV Infections / virology
  • HIV-1 / chemistry*
  • HIV-1 / metabolism
  • Humans
  • Kinetics
  • Magnetic Resonance Spectroscopy
  • Models, Molecular
  • Molecular Sequence Data
  • Mutation
  • Oligopeptides / chemistry*
  • Oligopeptides / genetics
  • Oligopeptides / pharmacology
  • Protein Binding
  • Protein Multimerization / drug effects*
  • Protein Structure, Secondary / drug effects
  • Protein Structure, Tertiary / drug effects
  • Recombinant Proteins / chemistry*
  • Recombinant Proteins / genetics
  • Recombinant Proteins / pharmacology
  • Software
  • Spectrometry, Fluorescence

Substances

  • Capsid Proteins
  • Oligopeptides
  • Recombinant Proteins